Analyst Reco. Immunic, Inc.

Equities

IMUX

US4525EP1011

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.24 ^USD	0.00%		+2.48%	-17.33%

Apr. 09	Transcript : Immunic, Inc. - Special Call
Mar. 21	Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating	Feb. 23	MT
Wedbush Adjusts Price Target on Immunic to $7 From $5, Maintains Outperform Rating	23-10-10	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	23-10-10	DJ
Wedbush Assumes Coverage of Immunic With Outperform Rating, Lowers Price Target to $5 From $7	23-01-31	MT
SVB Securities Downgrades Immunic to Market Perform From Outperform, Adjusts Price Target to $5 From $9	22-10-21	MT
Wedbush Adjusts Immunic's Price Target to $7 From $11 on Stock Dilution, Keeps Outperform Rating	22-10-21	MT
Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate	22-10-20	CI
HC Wainwright Assumes Immunic at Buy with $26 Price Target	22-09-19	MT
Wedbush Adjusts Immunic's Price Target to $11 From $14, Keeps Outperform Rating	22-08-05	MT
SVB Securities Adjusts Immunic's Price Target to $9 From $45, Keeps Outperform Rating	22-06-03	MT
Wedbush Adjusts Immunic's Price Target to $14 From $61, Removing IMU-838/Ulcerative Colitis From Model; Outperform Rating Kept	22-06-03	MT
Piper Sandler Adjusts Immunic's Price Target to $39 From $71, Reiterates Overweight Rating	22-05-18	MT
IMMUNIC : HC Wainwright Adjusts Immunic's Price Target to $25 from $40, Keeps Buy Rating	21-09-07	MT
IMMUNIC : Wedbush Adjusts Immunic's Price Target to $61 From $68, Citing Stock Dilution; Outperform Rating Kept	21-08-09	MT
IMMUNIC : Wedbush Trims Immunic's Price Target to $68 From $72 on Adjusted IMU-838/RRMS Timeline; Outperform Rating Kept	21-07-06	MT
IMMUNIC : Aegis Capital Initiates Immunic at Buy Rating With $55 Price Target	21-04-15	MT
IMMUNIC : JMP Securities Starts Immunic at Market Outperform With $55 Price Target	21-03-24	MT
IMMUNIC : Wedbush Adjusts Immunic's Price Target to $72 From $67, Keeps Outperform Rating	20-11-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer